This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Familial adenomatous polyposis(Familial adenomatous polyposis)(Familial adenomatous polyposis)

Classification codes: ICD-10 D12.6 (M8220/0) / V281 | Synonyms: FAP, adenomatous polyposis of the colon, Adenomatous polyposis coli (APC), Gardner syndrome (form with extracolonic manifestations), Attenuated FAP (AFAP) | Adult onset: Symptom onset or colorectal cancer diagnosis is common in early adulthood (20s–40s), but polyps begin in adolescence (teens to 20s)

Contents


1. History

Early descriptions and establishment of the concept of polyposis

The history of familial adenomatous polyposis (FAP) dates back to the late 19th century. In 1882, the British surgeon Cripps reported multiple rectal polyps in two brothers, and subsequently several physicians recorded similar familial cases. In the early 1900s it was recognized that patients with numerous polyps ultimately progressed to colorectal cancer, and it was established that this disease is not a simple individual lesion but a hereditary tumor syndrome with a clear family history. In particular, Lockhart-Mummery left a pioneering description in 1925 emphasizing the risk of progression of FAP to colorectal cancer.

Gardner syndrome and recognition of extracolonic manifestations

In the 1950s, Eldon J. Gardner reported a clinical variant accompanied by soft tissue tumors (epidermoid cysts), osteomas and dental abnormalities in addition to colonic polyposis, and this variant was named 'Gardner syndrome.' Subsequent research showed that Gardner syndrome and classic FAP are caused by the same APC gene variants, and it is now understood as part of the phenotypic spectrum of FAP.

Discovery of the APC gene

In 1987, linkage analysis confirmed that the FAP causative gene is located on the long arm of chromosome 5, and in 1991 the APC (Adenomatous Polyposis Coli) gene was independently cloned and identified by multiple research groups. The APC gene is a key negative regulator of the Wnt signaling pathway, and this discovery was a landmark turning point in understanding the molecular mechanisms of colorectal carcinogenesis.


2. Causes

APC gene germline variants

The cause of FAP is a heterozygous germline mutation of the APC gene (5q22.2). The APC protein is a component of a complex that binds β-catenin and promotes its degradation; when APC function is lost, β-catenin accumulates in the cell and abnormal transcriptional activation of Wnt target genes occurs. This leads to excessive activation of cell proliferation signals and promotes malignant transformation of colonic epithelial cells.

Somatic second hit (Two-hit hypothesis)

FAP is a typical hereditary tumor syndrome to which Knudson's two-hit hypothesis applies. A loss-of-function variant already exists in one APC allele in the germline (first hit), and polyps form when a somatic variant additionally occurs in the remaining normal APC allele in colonic cells (second hit). This second hit tends to occur specifically in the codon 1250–1464 region.

Cause of MYH-associated polyposis (MAP)

Some FAP-like phenotypes are caused not by APC gene variants but by heterozygous germline variants of the MUTYH (MYH) gene. MUTYH-associated polyposis (MAP) shows an autosomal recessive mode of inheritance, and polyps develop as G:C→T:A somatic mutations accumulate in multiple genes, including APC, due to defective repair of oxidative DNA damage (8-oxoguanine).


3. Genetics

APC gene structure and variant types

The APC gene is located at 5q22.2, contains 15 exons and encodes a protein of 2,843 amino acids. Germline variants associated with FAP are scattered throughout the gene, but frameshift and nonsense mutations in the codon 1–1600 range are particularly frequent. Codon 1309 (AAATAAAA deletion) is the most frequent single variant site, and variants at this site are associated with early onset and severe polyposis.

Genotype-phenotype correlation

The location of APC variants is closely correlated with the clinical phenotype. Variants between codons 1250 and 1464 are typically associated with severe FAP with more than 1,000 polyps, while variants before codon 169 or after codon 1600 are associated with attenuated FAP (AFAP, <100 polyps, later onset). The Gardner syndrome phenotype (desmoid tumors, osteomas, etc.) is particularly closely related to variants in the codon 1310–2011 range.

Attenuated FAP (AFAP) and MAP

Attenuated FAP (AFAP) is caused by variants at either end of the APC gene (exons 1–4 or part of exon 15); polyps are fewer (10–100), onset is later, and colorectal cancer occurs at a mean age of 50–55 years. MAP is caused by variants in both alleles of the MUTYH gene, such as Y179C and G396D (compound heterozygous or homozygous), and is transmitted by autosomal recessive inheritance. The number of polyps in MAP ranges from tens to hundreds, and differential diagnosis from classic FAP is needed.


4. General epidemiology

Incidence and prevalence

The incidence of FAP is estimated at about 1 in 8,000–10,000 births and is similar worldwide. Prevalence is reported at about 2.3–3.2 per 100,000 population. Males and females are equally affected, and there are no particular differences between races. About 20–25% of all FAP cases are due to new germline variants (de novo mutation) and occur without a family history.

Risk of colorectal cancer

In untreated patients with classic FAP, colorectal cancer develops in almost 100%. The mean age at diagnosis of colorectal cancer is about 39 years, decades earlier than sporadic colorectal cancer in the general population. Preventing colorectal cancer through early diagnosis and prophylactic surgery is the core of FAP treatment.

Status in Korea

Accurate statistics on the incidence of FAP in Korea are limited, but based on national cancer registry statistics and rare disease registry data, it is estimated that several hundred to several thousand patients are registered. Long-term follow-up is carried out through polyposis registries operated by major hospitals in Korea, and family surveillance and genetic counseling services are provided through hereditary colorectal cancer clinics.


5. Pathophysiology

Wnt-β-catenin signaling pathway

The core pathogenic mechanism of FAP is abnormal activation of the Wnt/β-catenin signaling pathway. Under normal conditions, the APC protein forms a complex with AXIN, GSK-3β, CK1α and others to phosphorylate β-catenin and induce its proteasomal degradation. When APC function is lost, β-catenin is not degraded, accumulates in the cytoplasm and moves to the nucleus, where it binds the transcription factors TCF/LEF and activates transcription of target genes related to cell proliferation, such as cyclin D1 and c-MYC. As a result, the proliferative compartment of the colonic crypts expands abnormally and adenomas form.

Adenoma-carcinoma continuum

In FAP, colorectal cancer development is an extreme form of the polyp-to-colorectal cancer progression (adenoma-carcinoma sequence). On top of genetic instability initiated by loss of APC function, KRAS mutations, SMAD4/DPC4 loss, TP53 mutations and others accumulate sequentially, and adenomas progress to high-grade dysplasia, carcinoma in situ and invasive colorectal cancer. In patients with FAP, this process proceeds in a much shorter time than in the general population and occurs simultaneously in multiple adenomas.

Pathogenesis of extracolonic lesions

Desmoid tumors are fibrous tumors that appear when APC gene abnormalities are expressed in fascia and connective tissue, and they are particularly frequent in patients with codon 1310–2011 variants. Congenital hypertrophy of the retinal pigment epithelium (CHRPE) appears as congenital hyperpigmented lesions on the fundus and is used in diagnostic screening of some APC variant carriers. The development of extracolonic cancers such as hepatoblastoma and (papillary) thyroid cancer is also explained by the somatic two-hit mechanism of APC.


6. Symptoms

Gastrointestinal symptoms

In classic FAP, colonic polyps usually begin to form in the teens to 20s, but in the early stage when there are only tens to hundreds of polyps, patients are often asymptomatic. When polyps increase to hundreds or thousands, bloody stools, diarrhea, abdominal pain, mucoid stools and iron deficiency anemia may appear. When it progresses to colorectal cancer, changes in bowel habits, weight loss and obstructive symptoms follow.

Extracolonic symptoms

Gastric and duodenal adenomatous polyps occur in more than 90% of patients with FAP, and polyps near the duodenal papilla carry a high risk of malignant transformation. Desmoid tumors commonly occur in the intra-abdominal mesentery and can cause serious complications through compression of surrounding organs, bowel obstruction, ureteral compression and so on. Facial deformity due to osteomas (jaw, skull) and dental abnormalities such as supernumerary and impacted teeth also appear.

Risk of thyroid, liver and other cancers

In patients with FAP, compared with the general population, the risk of thyroid cancer (papillary, more frequent in women) is increased about 100-fold and the risk of hepatoblastoma (mainly in children under 5) about 800-fold. Small bowel adenomas and adenocarcinomas, central nervous system tumors (Turcot syndrome, medulloblastoma), adrenal tumors and others have also been reported.


7. Signs

Endoscopic findings

On colonoscopy, a pattern of hundreds to thousands of adenomatous polyps carpeting the colonic mucosa is the typical finding of classic FAP. The polyps are mainly tubular adenomas, ranging in size from a few mm to several cm. On upper GI endoscopy, hyperplastic polyps of the gastric body (fundag gland polyp) are common, and the risk of duodenal adenomatous polyps is assessed according to the Spigelman classification.

Funduscopic findings

Congenital hypertrophy of the retinal pigment epithelium (CHRPE) is used to screen family members suspected of FAP without colonoscopy. Four or more bilateral CHRPE lesions show high specificity for the diagnosis of FAP. However, because CHRPE does not appear with all APC variant sites, its absence does not exclude FAP.

Skeletal and soft tissue findings

In Gardner syndrome, osteomas of the mandible and skull, epidermoid cysts of the skin, lipomas, fibromas and others are observed. Osteomas occur mainly in the maxillofacial region and cause facial asymmetry or discomfort.


8. Screening

Family surveillance and genetic testing

It is recommended that first-degree relatives (parents, siblings, children) of patients diagnosed with FAP have APC or MUTYH gene testing to determine whether they carry the variant. When a variant is confirmed by genetic testing, or when testing is not possible, management switches to clinical surveillance. Genetic counseling must be provided before and after testing so that patients and families fully understand the meaning of the test results and the future management plan.

Endoscopic surveillance

For APC variant carriers or high-risk family members, international guidelines recommend annual colonoscopy from age 10–15. When polyps are found, the degree of dysplasia is assessed by biopsy, and the timing of prophylactic surgery is determined. After surgery, the presence of polyps in the remaining rectum or ileal pouch is checked by follow-up endoscopy at 6–12-month intervals.

Upper GI and thyroid surveillance

Surveillance for duodenal adenomas by upper GI endoscopy (especially with a side-viewing duodenoscope) begins at the time of FAP diagnosis or from adulthood and is performed at 1–5-year intervals according to the Spigelman score. Annual thyroid ultrasound is considered, especially in young female patients with FAP.


9. Diagnosis

Clinical diagnostic criteria

The clinical diagnosis of FAP is made when 100 or more adenomatous polyps throughout the colon are confirmed. FAP is also strongly suspected when there is a family history, or when, even with fewer than 100 polyps, onset is in the teens to 20s or extracolonic FAP manifestations are present. Attenuated AFAP is characterized by 10–99 polyps, a mean age of onset in the 40s–50s and a predominantly right-sided colonic distribution.

Genetic testing

Germline variants of the APC gene are identified by methods such as Sanger sequencing, next-generation sequencing (NGS) and detection of large deletions and duplications (MLPA). When no APC variant is found, MUTYH gene testing is additionally performed to differentiate MAP. The variant detection rate is about 80–90% in classic FAP and somewhat lower, about 50–75%, in AFAP.

Pathologic diagnosis

The histopathologic findings of the polyps are tubular, villous and tubulovillous adenomas, and when high-grade dysplasia or dysplasia within carcinoma is identified, the timing of surgery may need to be moved forward. Desmoid tumors are characterized by fibrous proliferation of spindle cells, and positive nuclear β-catenin staining aids diagnosis.


10. Treatment

Prophylactic colectomy

The definitive treatment of FAP and the key to colorectal cancer prevention is prophylactic colectomy. Surgical options are ① total colectomy + ileorectal anastomosis (IRA): functionally advantageous because the rectum is preserved, but surveillance of polyps in the remaining rectum is required; and ② total proctocolectomy + ileal pouch-anal anastomosis (IPAA, J-pouch): removes the rectal mucosa to minimize cancer risk but has the disadvantage of increased bowel movement frequency. The timing of surgery is determined considering polyp density, degree of dysplasia, presence of symptoms, and patient age and preference, and it is generally performed in the late teens to 20s.

Drug therapy

COX-2 inhibitors (celecoxib) and sulindac have been shown in clinical trials to reduce the number of polyps in patients with FAP. However, because these drugs do not completely suppress polyp development, they are not recommended as a substitute for surgery, and they are used as adjuvant therapy before surgery or for the adjunctive purpose of suppressing polyps in the remaining rectum or ileal pouch after surgery.

Treatment of desmoid tumors

Desmoid tumors are difficult to treat and have a high recurrence rate. Surgical resection, radiation therapy and drug therapy (sulindac, tamoxifen, imatinib, sorafenib, etc.) are tried, and clinical studies of targeted agents such as gamma secretase inhibitors (nirogacestat) are currently under way.


11. Prognosis

Prognosis after colectomy

Early diagnosis and prophylactic colectomy can greatly reduce deaths from colorectal cancer. Even after surgery, polyps develop in the remaining rectum (after IRA) or the ileal pouch (after IPAA), so regular endoscopic follow-up is essential. The risk of cancer in the remaining rectum is reported at about 10–15% at 15 years after IRA.

Extracolonic cancers and desmoid tumors

Currently, the main causes of death in patients with FAP are duodenal cancer and desmoid tumors rather than colorectal cancer. The cumulative risk of duodenal cancer is about 4–10% by age 70, so regular duodenal endoscopic surveillance is important. Desmoid tumors often arise after postoperative mesenteric traction or trauma, and complications from recurrence and growth cause serious morbidity.

Quality of life

Patients who have undergone ileal pouch-anal anastomosis after prophylactic surgery experience 4–8 bowel movements a day, and fecal incontinence or nocturnal bowel movements can affect quality of life. The psychological burden of having a hereditary disease and anxiety about genetic risk within the family are also targets of management.


12. Prevention

Genetic counseling and family surveillance

The most effective approach to FAP prevention is to establish genetic counseling and a family surveillance system. Genetic testing is performed in first-degree relatives of confirmed patients to identify variant carriers early, and endoscopic surveillance and surgery are planned. Children carrying an APC variant undergo annual colonoscopy from age 10 to detect polyp development early.

Pharmacologic chemoprevention

Drugs such as sulindac and celecoxib show an adjunctive chemopreventive effect of reducing the polyp burden, but evidence that they prevent colorectal cancer itself is still insufficient. Recently, the chemopreventive potential of erlotinib, aspirin and others is also being studied.

Registry operation and multidisciplinary management

Several centers in Korea and abroad operate FAP polyposis registries and provide systematic surveillance and genetic counseling services to registered patients and family members. Integrated management through cooperation of a multidisciplinary team—gastroenterology, colorectal surgery, medical genetics, ophthalmology, thyroid surgery and others—is essential for improving the prognosis of patients with FAP.


13. References

  1. Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science. 1991;253(5020):661-665.
  2. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66(3):589-600.
  3. Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol. 2007;61(2):153-161.
  4. Bisgaard ML, Fenger K, Bülow S, et al. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat. 1994;3(2):121-125.
  5. Vasen HF, Möslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008;57(5):704-713.
  6. Bülow S, Christensen IJ, Höjen H, et al. Duodenal surveillance improves the prognosis after duodenal cancer in familial adenomatous polyposis. Colorectal Dis. 2012;14(8):947-952.
  7. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol. 2006;101(2):385-398.
  8. Bertario L, Russo A, Sala P, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer. 2001;95(2):102-107.
  9. Samadder NJ, Jasperson K, Burt RW. Hereditary and common familial colorectal cancer: evidence for colorectal surveillance. J Gastrointest Oncol. 2012;3(4):385-397.
  10. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet. 2001;10(7):721-733.
  11. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med. 2003;348(9):791-799.
  12. Latchford AR, Neale KF, Spigelman AD, et al. Features of duodenal cancer in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2009;7(6):659-663.